Vertex on the verge
More than two years after instituting Vertex 2.0, an approach that simultaneously looks at multiple chemistries against multiple targets in a gene family, Vertex Pharmaceuticals Inc. is still processing a clinical pipeline created by Vertex 1.0, a one-at-a-time drug discovery paradigm that placed its bets on a handful of enzymes.
Providing that the choice of targets derived from Vertex 1.0 has been sound, the built-in redundancies in its pipeline eventually should result in the company's third drug. And the first fruits of Vertex 2.0 are set to enter the clinic in the first half of 2004.
That does not mean